anti-human cd38 antibody, clone at-1, fitc  (STEMCELL Technologies Inc)

Journal: International Journal of Molecular Sciences

Article Title: Changes in the Phenotype and Metabolism of Peritoneal Macrophages in Mucin-2 Knockout Mice and Partial Restoration of Their Functions In Vitro After L-Fucose Treatment

doi: 10.3390/ijms26010013

Figure Lengend Snippet: Addition of fucose to the cell culture medium affected the production of cytokines, ATP and Ca 2+ levels, and surface and intracellular expression of CD38 of peritoneal macrophages derived from C57BL/6 and Muc2 −/− mice. ( A ). Inflammatory cytokine levels in cell culture medium of peritoneal macrophages from the two mouse strains with and without the addition of 0.1% L-fucose; the median, min, and max for each cytokine is presented in pg/mg protein. ( B ). ATP levels in the peritoneal macrophages of two mouse strains incubated with and without 0.1% L-fucose. ( C ). Ca 2+ levels in the peritoneal macrophages of the two mouse strains incubated with and without 0.1% L-fucose. ( D ). Percentage of peritoneal macrophages with surface CD38 expression from the two mouse strains incubated with and without 0.1% L-fucose. ( E ). Percentage of peritoneal macrophages with intracellular CD38 expression from the two mouse strains incubated with and without 0.1% L-fucose. “C57BL/6” vs. “ Muc2 −/− “ and “with 0.1% L-fucose” vs. “without 0.1% L-fucose”: * p < 0.05, ** p < 0.01, and *** p < 0.001. Two-way PERMANOVA test.

Article Snippet: After centrifugation, the cells were resuspended in 100 μL of permeabilization buffer and incubated with Pacific Blue–anti-CD45 (BioLegend, San Diego, CA, USA, Rat IgG2b, k, clone S18009F), PE-anti-CD11b (BioLegend, USA, Rat IgG2b, k, clone M1/70), and FITC-anti-CD38 (Invitrogen, Waltham, MA, USA, clone 90) for 60 min at 4 °C in the dark.

Techniques: Cell Culture, Expressing, Derivative Assay, Incubation

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Enhanced T cell activation and cytotoxicity against AML via targeted anti-CD99 nanoparticle treatment

doi: 10.1016/j.biopha.2024.117265

Figure Lengend Snippet: α-CD99-A192 increases expression of activation marker CD38 but does not affect T cell major phenotypes. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated PBMCs for A, CD3 , B, CD4 , C, CD8 and D, CD25. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated expanded T cells for E, CD3 , F, CD4 , G, CD8 and H, CD25. I, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated PBMCs. J, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated T cells. K, Flow cytometry panel of CD3 + CD69 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. L, Flow cytometry panel of CD3 + CD38 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. M, Percentage of CD69 + for A192 and α-CD99-A192 treated t cells where no significant change is observed in the α-CD99-A192 treated T cells compared with the control. N, Percentage of CD38 + for A192 and α-CD99-A192 treated T cells where a significant increase is observed in the α-CD99-A192 treated T cells compared with the control. The differences between the groups were analyzed using unpaired t tests (**,P<0.01; *,P<0.05). The experiments were performed utilizing samples obtained from three donors for T cell phenotyping and five donors for CD69 and CD38 activation marker analysis. The T cells utilized in these experiments were expanded using PHA and IL2 from the PBMCs obtained from healthy donors.

Article Snippet: Anti-Human CD3 PerCP-Cyanine 5.5 (Clone: OKT3; eBioscience, Cat#45–0037–42), Anti-Human CD38 FITC (Clone: HB7; eBioscience, Cat#11–0388) and Anti-Human CD69 PE (Clone: FN50; eBioscience, Cat#12–0699) was added to the cells.

Techniques: Expressing, Activation Assay, Marker, Flow Cytometry, Control

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Enhanced T cell activation and cytotoxicity against AML via targeted anti-CD99 nanoparticle treatment

doi: 10.1016/j.biopha.2024.117265

Figure Lengend Snippet: α-CD99-A192 treated T cells show increased cytotoxicity against leukemic cells. Flow cytometry panels showing. A, Annexin V positive cells at 18 hours B, FITC + live MV4–11 cells at 18 hours C, Annexin V positive cells at 48 hours D, FITC + MV4–11 cells at 48 hours for A192 and α-CD99-A192 treated T cells cocultured with leukemic MV4–11 cells at an E:T ratio of 5:1. Co-culture assays showed E, greater apoptosis in MV4–11 cells at 18 hours, but no significant apoptosis in MV4–11 cells at 48 hours and F, a reduction in viable leukemic cells at 18 and 48 hours in α-CD99-A192 treated T cells cocultured with leukemic MV4–11 cells at an E:T ratio of 5:1 compared with control. Flow cytometry panels showing Annexin V positive FITC − T cells G , 18 hours and H , 48 hours. I , Co-culture assays showed no significant toxicity to T cells at 18 hours and 48 hours. Luciferase assay also exhibited a reduction in viable leukemic cells in α-CD99-A192 treated T cells cocultured with leukemic J, MV4–11 cells, K, THP-1 and L, MOLM-13 cells at an E:T ratio of 5:1 compared with control. The differences between the groups were analyzed using unpaired t tests (***,P<0.001; **,P<0.01; *,P<0.05). The experiments were performed utilizing samples obtained from three donors.

Article Snippet: Anti-Human CD3 PerCP-Cyanine 5.5 (Clone: OKT3; eBioscience, Cat#45–0037–42), Anti-Human CD38 FITC (Clone: HB7; eBioscience, Cat#11–0388) and Anti-Human CD69 PE (Clone: FN50; eBioscience, Cat#12–0699) was added to the cells.

Techniques: Flow Cytometry, Co-Culture Assay, Control, Luciferase

Journal: Cell Reports Methods

Article Title: Generation, expansion, gene delivery, and single-cell profiling in rhesus macaque plasma B cells

doi: 10.1016/j.crmeth.2024.100878

Figure Lengend Snippet:

Article Snippet: anti-CD38 FITC clone: OKT10 , Caprico Biotechnologies , 100815.

Techniques: Enzyme-linked Immunospot, Isolation, Enzyme-linked Immunosorbent Assay, Recombinant, Software